Society of Hematologic Oncology

Society of Hematologic Oncology Become a member of SOHO today for free! SSAUNQ 2024 | November 22, 2024 | Virtual SOHO is led by a Board of Directors with six voting members.

SOHO is the only international society for clinicians, scientists & related professionals who specialize in the research & treatment of hematologic malignancies. The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic maligna

ncies and related disorders. Since that time, nearly 3,000 members have joined the society from around the globe. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO. Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively.

“Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (click the 'Sign Up' button to become a SOHO member). The SOHO Fifth Annual Meeting is scheduled for September 13-16, 2017 at the Westin Galleria and Oaks in Houston, Texas. The society expects more than 1,000 physicians and related professionals to attend the 3.5-day event. (go to soho2017.com for more information and registration).

“You made the possible impossible.” Attendee comment at Brandon Imber’s () presentation on split-course radiotherapy pri...
06/18/2025

“You made the possible impossible.” Attendee comment at Brandon Imber’s () presentation on split-course radiotherapy prior to -T in R/R BCL

Rise and shine . Never gets old!
06/18/2025

Rise and shine . Never gets old!

🚨Early bird registration is now open for !🚨Join top experts and thousands of professionals from around the globe this...
04/16/2025

🚨Early bird registration is now open for !🚨

Join top experts and thousands of professionals from around the globe this Sept. 3-6 in Houston, TX (or virtually!) for 3.5 days of cutting-edge discussions on the latest advances in blood cancers. Don’t miss this chance to network with world-renowned leaders in hematologic oncology!

✅Early bird rates are available for a limited time – register today to secure your spot at soho.click/2025 (🔗 in bio!)

👋 Meet Dr. Andres Ramirez, a 2024 SOHO Young Investigator Program (YIP) award recipient whose groundbreaking research in...
04/14/2025

👋 Meet Dr. Andres Ramirez, a 2024 SOHO Young Investigator Program (YIP) award recipient whose groundbreaking research in Waldenström macroglobulinemia is shaping the future of blood cancer treatment! For Dr. Ramirez, the YIP scholarship was more than a ticket to the SOHO Annual Meeting, it was a career-changing opportunity to connect, collaborate, and advance patient care.

💰Your donation helps early-career researchers like Dr. Ramirez attend the SOHO Annual Meeting - fueling discoveries and nurturing the next generation of oncology leaders.

💪Show your support! Donate $50+ and receive an exclusive thank-you gift at the upcoming SOHO Annual Meeting in Houston.

🔗 Donate today at soho.click/donate (link in bio!)

Support progress in hematologic malignancies by donating to SOHO’s special fundraising initiative - live now through the...
04/05/2025

Support progress in hematologic malignancies by donating to SOHO’s special fundraising initiative - live now through the 13th Annual Meeting in Houston, Sept 3–6, 2025! Your generous, tax-deductible gift fuels education, scholarships for young investigators, and our global SOHO Ambassador network. Let’s advance the science together

Learn more at the 🔗 in our bio!

ACROBAT interim results support AlloHeme for relapse prediction in , CareDx, Inc.
02/14/2025

ACROBAT interim results support AlloHeme for relapse prediction in ,

CareDx, Inc.

Interim results of the ACROBAT study suggest that increasing microchimerism and loss of complete chimerism may indicate relapse risk in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The findings were presented in an oral abstract1 at the 2025 Transportation and Cell...

Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?
01/28/2025

Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?

A study found that “pacritinib may offer a unique survival advantage” for patients with myelofibrosis (MF) and thrombocytopenia who achieve any spleen volume reduction (SVR). The study was led by Helen Ajufo, MD, of Washington University School of Medicine in St. Louis, Missouri, and published i...

Dr. Garcia-Manero discusses mature data on luspatercept’s efficacy in MDSWatch the video:
01/23/2025

Dr. Garcia-Manero discusses mature data on luspatercept’s efficacy in MDS

Watch the video:

Guillermo Garcia-Manero MD, of the University of Texas MD Anderson Cancer Center, discusses long-term data from the COMMANDS trial, highlighting the use of luspatercept (Reblozyl) as a first-line treatment for lower-risk myelodysplastic syndromes (MDS). After 1.5 years, one-third of patients maintai...

We're proud to announce and welcome our newest SOHO Corporate Partner, Autolus! Learn more about Autolus at www.autolus...
01/22/2025

We're proud to announce and welcome our newest SOHO Corporate Partner, Autolus! Learn more about Autolus at www.autolus.com

Learn more about SOHO Corporate Partnerships👉 http://soho.click/partner

Subscribe to http://sohoinsider.com, the one and only official news source of the Society of Hematologic Oncology. (Plea...
01/14/2025

Subscribe to http://sohoinsider.com, the one and only official news source of the Society of Hematologic Oncology. (Please note that Blood Cancers Today is no longer affiliated with SOHO.)

Presence of circulating lymphoma cells a significant adverse risk factor in DLBCL
01/09/2025

Presence of circulating lymphoma cells a significant adverse risk factor in DLBCL

The largest study to date evaluating the impact of circulating lymphoma cells (CL) on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma (DLBCL) found that presence of CL at diagnosis was associated with inferior response rates and survival compared to those without CL.....

Address

Houston, TX

Opening Hours

Monday 8am - 6pm
Tuesday 8am - 6pm
Wednesday 8am - 6pm
Thursday 8am - 6pm
Friday 8am - 6pm

Telephone

+12813647387

Website

Alerts

Be the first to know and let us send you an email when Society of Hematologic Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Society of Hematologic Oncology:

Shortcuts

Share

Category

About the Society

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 3,000 members have joined the society from around the globe. SOHO is led by a Board of Directors with eight voting members. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO. Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively. “Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (click the 'Sign Up' button to become a SOHO member). The SOHO Sixth Annual Meeting is scheduled for September 12-15, 2018 at the Hilton Americas-Houston in Houston, Texas. The society expects approximately 1,200 physicians and related professionals to attend the 3.5-day event. (go to soho2018.org for more information, abstract submissions and registration).